Over-expression of cell surface antigens on leukemia cells has been exploited for therapeutic purposes e.g. Blinatumomab[18, 19] and CAR-T cell antigens against CD19 in B cell precursor (BCP) ALL.[20–22] Unfortunately, there is a lack of such targeted therapies for T-ALL. Here, CD19 is linked to acute lymphoblastic leukemia.